A Safety Study of Intraoperative Radiation Therapy Following Stereotactic Body Radiation Therapy and Multi-agent Chemotherapy in the Treatment of Localized Pancreatic Adenocarcinoma
Summary
This study is designed to investigate the safety of intraoperative radiation therapy (IORT) in patients with localized pancreatic cancer undergoing surgical resection after neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT).
Detailed description
Standard of care treatment for patients with non-metastatic pancreatic adenocarcinoma (PDAC) includes chemotherapy and Stereotactic Body Radiation Treatment (SBRT) followed by surgical resection of the tumor with or without Intra-Operative Radiation Therapy (IORT). There is some evidence from other research studies suggesting that adding radiation treatment during the surgical resection may improve local control of the cancer. The use of IORT plus surgical resection can be used to treat pancreatic cancer and is done on a case by case basis at Johns Hopkins. The department of Radiation Oncology has developed a program using a High Dose Rate-IORT (HDR-IORT). The HDR-IORT makes it possible to deliver concentrated radiation dose at the surface of the tumor. Our team has shown in previous studies that the majority of cancer cells that remain after treatment are located around the area of the pancreas called the "Triangle Volume" (TV). This region contains blood vessels, lymphatic vessels, and nerves, and is at high risk of containing cancer cells. This region is difficult to treat with SBRT alone because of being close to normal, healthy organs. Therefore, this study involves using IORT to treat the TV to a therapeutic radiation dose. The part of the treatment that is considered research is: * Giving one dose of 15 Gy during the surgery using IORT to deliver radiation, and * Targeting the larger area around the pancreas called the TV The goal of this study is to determine safety of this added treatment which will be assessed at 3 months after the surgery is completed.
Arms & interventions
- RadiationHigh Dose Rate Brachytherapy (HDR) Intraoperative Radiation Therapy (IORT)
After the patient receives standard of care treatment, they will receive a single dose of radiation (15 Gy) at the time the tumor is surgically removed. Surgeons will then place clips along the blood vessels around the surgical area. These clips will be used to confirm (after surgery) that the expected dose of radiation was received during surgery.
Outcome measures
Primary
Acute post-operative toxicity of targeted IORT
To evaluate acute post-operative toxicity of IORT targeted to the TV in patients with non-metastatic PDAC undergoing surgical resection after neoadjuvant multi-agent chemotherapy and SBRT.
Time frame: 3 months
Secondary
Late post-operative toxicity of targeted IORT
Time frame: 6 months
Late post-operative toxicity of targeted IORT
Time frame: 12 months
Late post-operative toxicity of targeted IORT
Time frame: 24 months
Late post-operative toxicity of targeted IORT
Time frame: 36 months
Median local-progression free survival (LPFS) from IORT
Time frame: 6 months
Median local-progression free survival (LPFS) from IORT
Time frame: 12 months
Median local-progression free survival (LPFS) from IORT
Time frame: 24 months
Median local-progression free survival (LPFS) from IORT
Time frame: 36 months
Median overall survival (OS) from IORT
Time frame: 6 months
Median overall survival (OS) from IORT
Time frame: 12 months
Median overall survival (OS) from IORT
Time frame: 24 months
Median overall survival (OS) from IORT
Time frame: 36 months
Median progression free survival (PFS) from IORT
Time frame: 6 months
Median progression free survival (PFS) from IORT
Time frame: 12 months
Median progression free survival (PFS) from IORT
Time frame: 24 months
Median progression free survival (PFS) from IORT
Time frame: 36 months
Eligibility criteria
Study locations (1)
Johns Hopkins Hospital
Baltimore, Maryland, 21205
References
- Reddy AV, Hill CS, Zheng L, He J, Narang AK. A safety study of intraoperative radiation therapy following stereotactic body radiation therapy and multi-agent chemotherapy in the treatment of localized pancreatic adenocarcinoma: study protocol of a phase I trial. Radiat Oncol. 2022 Oct 28;17(1):173. doi: 10.1186/s13014-022-02145-9.(PubMed)